Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Envita Medical Center, Inc.
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00909558CT.gov Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Natural Killer / Natural Killer T Cell Immunotherapy (this asset) | Envita Medical Center, Inc. | P1 | C · 39 |
| Olutasidenib | Rigel Pharmaceuticals | P4 | BB |
| Irinotecan | Kailin Yang, MD, PhD | P3 | B |
| Valproic Acid | Medical University of South Carolina | P2 | B |
| Dianhydrogalactitol | Kintara Therapeutics, Inc. | P2 | B |
| Cyclophosphamide | Essen Biotech | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Eli Lilly and Company | P1/2 | B |
| Camustine | University of California, Davis | P3 | B |
| Carboplatin | DelMar Pharmaceuticals, Inc. | P3 | B |
+42 more in the Glioma cohort
Other indications for Autologous Natural Killer / Natural Killer T Cell Immunotherapy
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P1 | CC · 43 |
| Squamous Cell Lung Carcinoma | — | P1 | CC · 43 |
| Colon Carcinoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Natural Killer / Natural Killer T Cell Immunotherapy in Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-natural-killer-natural-killer-t-cell-immunotherapy-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →